17-iodoheptadecanoic-acid and Liver-Cirrhosis--Alcoholic

17-iodoheptadecanoic-acid has been researched along with Liver-Cirrhosis--Alcoholic* in 2 studies

Other Studies

2 other study(ies) available for 17-iodoheptadecanoic-acid and Liver-Cirrhosis--Alcoholic

Article	Year
17-Iodine-123 iodoheptadecanoic acid for metabolic liver studies in humans. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 1986, Volume: 27, Issue:10 (17-123I)-Iodoheptadecanoic acid ([123I]HA) was used for dynamic planar scintigraphy of the liver in normal individuals (control I), in patients without liver disease but with elevated serum cholesterol and/or triglycerides (control II), and in patient groups with alcohol-induced fatty liver (PG I), fatty liver not due to alcohol (PG II), alcohol-induced liver cirrhosis (PG III), or liver cirrhosis of the posthepatitic type (PG IV). Tracer uptake and elimination time were assayed in different liver regions; mean elimination time was expressed for total liver. In control I, tracer uptake was homogeneous, and mean elimination time was 20.7 +/- 5.3 min without significant local variations. In control II, tracer uptake was reduced but homogeneous and mean elimination time was 59.4 +/- 35.8 min with some local variations. In PG I, uptake was reduced and inhomogeneous and elimination time was the same as in control I, irrespective of cholesterol and triglyceride values. In PG II, uptake was the same as in PG I but mean elimination time was 48 +/- 8.1 min with some local variations. In PG III, uptake was extremely reduced and spotty and elimination time correlated with the severity of disease from 19 to 881 min in different liver regions. Topics: Fatty Acids; Fatty Liver; Fatty Liver, Alcoholic; Humans; Iodine Radioisotopes; Liver; Liver Cirrhosis; Liver Cirrhosis, Alcoholic; Liver Diseases; Radionuclide Imaging	1986
Fast, low-temperature preparation of carrier-free 17-123I-heptadecanoic acid applied for liver and heart scintigraphy. European journal of nuclear medicine, 1986, Volume: 11, Issue:9 A high-yield method for labelling 17-I-heptadecanoic acid with 123I is described, and a clinical evaluation of the radiopharmaceutical is given. The labelling procedure is based on the use of a conventional ultrasonic bath. It was found that the addition of thiosulphate to the reaction medium avoids the formation of labelled side products and increases the yield considerably. The carrier-free 17-123I-heptadecanoic acid (2 mCi) in 6% human serum albumin was injected IV for heart and liver studies on selected patients with cirrhosis (alcoholic, post-necrotic) and diabetes. Topics: Diabetes Mellitus, Type 1; Fatty Acids; Heart; Humans; Kinetics; Liver; Liver Cirrhosis; Liver Cirrhosis, Alcoholic; Myocardium; Radionuclide Imaging; Temperature; Time Factors	1986

Article

Year

17-Iodine-123 iodoheptadecanoic acid for metabolic liver studies in humans.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 1986, Volume: 27, Issue:10

(17-123I)-Iodoheptadecanoic acid ([123I]HA) was used for dynamic planar scintigraphy of the liver in normal individuals (control I), in patients without liver disease but with elevated serum cholesterol and/or triglycerides (control II), and in patient groups with alcohol-induced fatty liver (PG I), fatty liver not due to alcohol (PG II), alcohol-induced liver cirrhosis (PG III), or liver cirrhosis of the posthepatitic type (PG IV). Tracer uptake and elimination time were assayed in different liver regions; mean elimination time was expressed for total liver. In control I, tracer uptake was homogeneous, and mean elimination time was 20.7 +/- 5.3 min without significant local variations. In control II, tracer uptake was reduced but homogeneous and mean elimination time was 59.4 +/- 35.8 min with some local variations. In PG I, uptake was reduced and inhomogeneous and elimination time was the same as in control I, irrespective of cholesterol and triglyceride values. In PG II, uptake was the same as in PG I but mean elimination time was 48 +/- 8.1 min with some local variations. In PG III, uptake was extremely reduced and spotty and elimination time correlated with the severity of disease from 19 to 881 min in different liver regions.

Topics: Fatty Acids; Fatty Liver; Fatty Liver, Alcoholic; Humans; Iodine Radioisotopes; Liver; Liver Cirrhosis; Liver Cirrhosis, Alcoholic; Liver Diseases; Radionuclide Imaging

1986

Fast, low-temperature preparation of carrier-free 17-123I-heptadecanoic acid applied for liver and heart scintigraphy.

European journal of nuclear medicine, 1986, Volume: 11, Issue:9

A high-yield method for labelling 17-I-heptadecanoic acid with 123I is described, and a clinical evaluation of the radiopharmaceutical is given. The labelling procedure is based on the use of a conventional ultrasonic bath. It was found that the addition of thiosulphate to the reaction medium avoids the formation of labelled side products and increases the yield considerably. The carrier-free 17-123I-heptadecanoic acid (2 mCi) in 6% human serum albumin was injected IV for heart and liver studies on selected patients with cirrhosis (alcoholic, post-necrotic) and diabetes.

Topics: Diabetes Mellitus, Type 1; Fatty Acids; Heart; Humans; Kinetics; Liver; Liver Cirrhosis; Liver Cirrhosis, Alcoholic; Myocardium; Radionuclide Imaging; Temperature; Time Factors

1986